-+ 0.00%
-+ 0.00%
-+ 0.00%

Sino Biopharm says NMPA clears TQF6422 obesity drug candidate for clinical trial

PUBT·08/21/2026 10:17:50
Listen to the news
Sino Biopharm says NMPA clears TQF6422 obesity drug candidate for clinical trial
  • Sino Biopharmaceutical unit Chia Tai Tianqing secured NMPA clearance to start clinical studies of TQF6422 obesity injection.
  • ActRII A/B-targeting monoclonal antibody to be tested for weight management in obese adults, or overweight adults with at least one comorbidity.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sino Biopharmaceutical Limited published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260821-12294335), on August 21, 2026, and is solely responsible for the information contained therein.